EHA 2025: Impact of Treating MRD Relapse Post 1L in Multiple Myeloma

Frida Bugge Askeland from the Oslo Myeloma Center presents findings from the Norwegian REMNANT study in this MEDtalk. The study investigates whether early intervention at MRD relapse following first-line (1L) treatment can improve progression-free survival (PFS) and overall survival (OS) in patients with multiple myeloma (MM).